E7386 enhances lenvatinib’s antitumor activity in preclinical models and human hepatocellular carcinoma.

ABSTRACT: To study the antitumor and antiangiogenic activity of combining E7386 (an oral protein-protein interaction inhibitor targeting CREB-binding protein (CBP)/β-catenin) with lenvatinib and explore a novel mechanism of action of E7386 that boosts antitumor response.

ORGANISM(S): Mus musculus Homo sapiens

PROVIDER: GSE299215 | GEO | 2025/08/21

REPOSITORIES: GEO